In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Cagrilintide | Synthetic analog Semaglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 130 | 4,624 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 28 (28 in people) | 1,224 (1,221 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 53 · 18 active1 more mentions it but does not test it | 663 · 284 active124 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Cagrilintide | Semaglutide |
|---|---|---|
| Body weightMetabolic and weight | 452421 | 969954105 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Ozempic says: “Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reduce the risk of sustained eGFR decline…”
| Adverse eventsWhole body | 1616 | 7757723 |
|---|
| Glycemic controlMetabolic and weight | 1293 | 66866512 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 99 | 345345 |
|---|
| LipidsCardiovascular | 22 | 1181171 |
|---|
| MortalityWhole body | 22 | 1041031 |
|---|
| Blood pressureCardiovascular | 33 | 9999 |
|---|
| PharmacokineticsPharmacology | 10811 | 93894 |
|---|
| Appetite and food intakeMetabolic and weight | 1111 | 97952 |
|---|
| Heart functionCardiovascular | 11 | 67616 |
|---|
| Metabolic pathways and metabolomicsMetabolic and weight | 22 | 99 |
|---|
| Hormone levelsEndocrine and hormones | 11 | 44 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Cagrilintide differs from Amylin, human (islet amyloid polypeptide) at 6 positions and carries 2 added groups.
What is different
Semaglutide differs from Glucagon-like peptide 1 (7-37) at 2 positions and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 53 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S7,101 participants1 Mar 2023 to est. 14 Oct 2027
Cardiovascular Disease
Novo Nordisk A/S3,400 participants1 Nov 2022 to est. 19 Oct 2026
Obesity
Novo Nordisk A/S2,734 participants27 Sept 2023 to 6 Jan 2026
Type 2 Diabetes Mellitus
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 663 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S17,604 participants24 Oct 2018 to 29 Jun 2023
Overweight · Obesity
Novo Nordisk A/S9,651 participants17 Jun 2019 to 23 Aug 2024
Diabetes Mellitus, Type 2
Novo Nordisk A/S3,533 participants17 Jun 2019 to 9 Jan 2024
Diabetes Mellitus, Type 2
124 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Cagrilintide | Semaglutide |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in percentage points | −0.9 percentage points HbA1c change from baseline Dose studied: 2.4 mg once weekly (escalated)32 weeksn = 302023 | −1.5 % points HbA1c change 52 weeksn = 1,7482022 |
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −18.4% Relative bodyweight change Dose studied: cagrilintide 2·4 mg plus semaglutide 2·4 mg once weekly68 weeksn = 3312026 | |
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in nmol/l | 6.14 to 170 nmol/L Cmax · cagrilintide 0.16-4.5 mg Dose studied: 0.16-4.5 mgn not reported2021 | |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 41 to 63% Gastrointestinal adverse events · cagrilintide 0.3-4.5 mg Placebo: 32% Dose studied: 0.3-4.5 mgn not reported2021 | |
| Adverse eventsMetabolic and weightCompared as: share of people in the arm that got the peptide, in % | 97% Participants with adverse events · cagrilintide 0.16-4.5 mg Placebo: 96% Dose studied: 0.16-4.5 mgn = 952021 |
−0.9 percentage points
HbA1c change from baseline
Dose studied: 2.4 mg once weekly (escalated)32 weeksn = 302023
−1.5 % points
HbA1c change
52 weeksn = 1,7482022
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Cagrilintide | Semaglutide |
|---|---|---|
| Hormone levelsEndocrine and hormonesCompared as: value in the arm that got the peptide, in pg/ml | No comparable result 1 randomized-trial result measure it in another way or another unit. | 88.3 pg/mL Absolute change in glucagon Placebo: 83.1 pg/mL 12 weeksn = 35 |
−18.7%
Mean bodyweight change · semaglutide 7.2 mg
Placebo: −3.9%
Dose studied: 7.2 mg once weekly72 weeksn = 1,2062025
28.8 nmol/l Cmax,ss · semaglutide 0.5 mg Dose studied: 0.5 mg once weeklyn not reported2021 |
41.8% Gastrointestinal adverse events Dose studied: 1.0 mg once weekly56 weeksn = 8132018 |
80% Patients with adverse events · oral semaglutide 7 mg Dose studied: 7 mg once daily57 weeksn = 1322020 |
−18.4%
Relative bodyweight change
Dose studied: cagrilintide 2·4 mg plus semaglutide 2·4 mg once weekly68 weeksn = 3312026
−18.7%
Mean bodyweight change · semaglutide 7.2 mg
Placebo: −3.9%
Dose studied: 7.2 mg once weekly72 weeksn = 1,2062025
6.14 to 170 nmol/L
Cmax · cagrilintide 0.16-4.5 mg
Dose studied: 0.16-4.5 mgn not reported2021
28.8 nmol/l
Cmax,ss · semaglutide 0.5 mg
Dose studied: 0.5 mg once weeklyn not reported2021
41 to 63%
Gastrointestinal adverse events · cagrilintide 0.3-4.5 mg
Placebo: 32%
Dose studied: 0.3-4.5 mgn not reported2021
41.8%
Gastrointestinal adverse events
Dose studied: 1.0 mg once weekly56 weeksn = 8132018
97%
Participants with adverse events · cagrilintide 0.16-4.5 mg
Placebo: 96%
Dose studied: 0.16-4.5 mgn = 952021
80%
Patients with adverse events · oral semaglutide 7 mg
Dose studied: 7 mg once daily57 weeksn = 1322020
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | −17% Loop diuretic dose decrease · Shown as a change. The study reports a loop diuretic dose decrease of this size. Dose studied: 2.4 mg once weekly52 weeksn not reported2024 |
|---|
| Blood pressureCardiovascularCompared as: difference from placebo, in mm hg | No randomized trial result 3 results from other study designs. | −3.84 mm Hg SBP change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| LipidsMetabolic and weightCompared as: difference from placebo, in % | No randomized trial result 2 results from other study designs. | −7% Total cholesterol change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 |
|---|
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in % | No randomized trial result 11 results from other study designs. | 8% Paracetamol AUC0-5h increase Dose studied: 2.4 mg once weekly (dose-escalated)20 weeksn = 722021 |
|---|
No comparable result
1 randomized-trial result measure it in another way or another unit.
88.3 pg/mL
Absolute change in glucagon
Placebo: 83.1 pg/mL
12 weeksn = 352018
No comparable result
1 randomized-trial result measure it in another way or another unit.
−17%
Loop diuretic dose decrease · Shown as a change. The study reports a loop diuretic dose decrease of this size.
Dose studied: 2.4 mg once weekly52 weeksn not reported2024
No randomized trial result
3 results from other study designs.
−3.84 mm Hg
SBP change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No randomized trial result
2 results from other study designs.
−7%
Total cholesterol change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
No randomized trial result
11 results from other study designs.
8%
Paracetamol AUC0-5h increase
Dose studied: 2.4 mg once weekly (dose-escalated)20 weeksn = 722021